View ValuationAdimmune 将来の成長Future 基準チェック /06現在、 Adimmuneの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長31.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Dec 06Consensus EPS estimates increase by 26%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from NT$2.10b to NT$2.18b. EPS estimate increased from NT$0.50 to NT$0.63 per share. Net income forecast to shrink 58% next year vs 38% growth forecast for Biotechs industry in Taiwan . Consensus price target of NT$52.00 unchanged from last update. Share price was steady at NT$36.60 over the past week.Price Target Changed • Apr 27Price target decreased to NT$53.00Down from NT$70.00, the current price target is provided by 1 analyst. New target price is 31% above last closing price of NT$40.50. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$0.34 for next year compared to NT$0.10 last year.すべての更新を表示Recent updatesReported Earnings • May 20First quarter 2026 earnings released: NT$0.44 loss per share (vs NT$0.53 loss in 1Q 2025)First quarter 2026 results: NT$0.44 loss per share (improved from NT$0.53 loss in 1Q 2025). Revenue: NT$82.3m (up 14% from 1Q 2025). Net loss: NT$185.5m (loss narrowed 17% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 23% per year.お知らせ • Mar 12Adimmune Corporation, Annual General Meeting, Jun 04, 2026Adimmune Corporation, Annual General Meeting, Jun 04, 2026. Location: no,328, chun fu rd., pei tun district, taichung city TaiwanReported Earnings • Nov 16Third quarter 2025 earnings released: NT$0.04 loss per share (vs NT$0.63 profit in 3Q 2024)Third quarter 2025 results: NT$0.04 loss per share (down from NT$0.63 profit in 3Q 2024). Revenue: NT$475.3m (down 47% from 3Q 2024). Net loss: NT$18.3m (down 107% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.52 loss per share (vs NT$0.65 loss in 2Q 2024)Second quarter 2025 results: NT$0.52 loss per share (improved from NT$0.65 loss in 2Q 2024). Revenue: NT$108.6m (up 36% from 2Q 2024). Net loss: NT$218.8m (loss narrowed 20% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.Reported Earnings • May 16First quarter 2025 earnings released: NT$53.00 loss per share (vs NT$0.44 loss in 1Q 2024)First quarter 2025 results: NT$53.00 loss per share (further deteriorated from NT$0.44 loss in 1Q 2024). Revenue: NT$72.1m (up 64% from 1Q 2024). Net loss: NT$223.3m (loss widened 21% from 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.お知らせ • May 07Adimmune Corporation to Report Q1, 2025 Results on May 13, 2025Adimmune Corporation announced that they will report Q1, 2025 results on May 13, 2025お知らせ • Mar 13Adimmune Corporation, Annual General Meeting, Jun 26, 2025Adimmune Corporation, Annual General Meeting, Jun 26, 2025. Location: no,328, chun fu rd., pei tun district, taichung city TaiwanNew Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change).分析記事 • Jan 13There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price RiseAdimmune Corporation ( TWSE:4142 ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.62 (vs NT$0.63 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.62 (down from NT$0.63 in 3Q 2023). Revenue: NT$888.2m (down 8.7% from 3Q 2023). Net income: NT$263.3m (flat on 3Q 2023). Profit margin: 30% (up from 27% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Mei-Ling Hsiao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Aug 13Little Excitement Around Adimmune Corporation's (TWSE:4142) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 7.2x Adimmune Corporation ( TWSE:4142 ) is definitely a...お知らせ • Aug 06Adimmune Corporation to Report Q2, 2024 Results on Aug 13, 2024Adimmune Corporation announced that they will report Q2, 2024 results on Aug 13, 2024Reported Earnings • May 18First quarter 2024 earnings released: NT$0.44 loss per share (vs NT$0.59 loss in 1Q 2023)First quarter 2024 results: NT$0.44 loss per share (improved from NT$0.59 loss in 1Q 2023). Revenue: NT$43.9m (down 74% from 1Q 2023). Net loss: NT$184.0m (loss narrowed 26% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.お知らせ • May 05Adimmune Corporation to Report Q1, 2024 Results on May 10, 2024Adimmune Corporation announced that they will report Q1, 2024 results on May 10, 2024Reported Earnings • Mar 31Full year 2023 earnings released: NT$1.52 loss per share (vs NT$0.68 profit in FY 2022)Full year 2023 results: NT$1.52 loss per share (down from NT$0.68 profit in FY 2022). Revenue: NT$1.79b (down 21% from FY 2022). Net loss: NT$639.9m (down 320% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Mar 14Adimmune Corporation, Annual General Meeting, Jun 21, 2024Adimmune Corporation, Annual General Meeting, Jun 21, 2024. Location: No. 328, Junfu 18th Rd., Beitun Dist., Taichung City Taiwan Agenda: To consider 2023 Business Report; to consider audit Committee's review of the 2023 Annual Final Accounting Books and Statements; to consider election for one additional seat of independent director; and to transact other business.お知らせ • Nov 02Adimmune Corporation Announces Change in Representative of its Institutional DirectorAdimmune Corporation announced the change in representative of the company’s institutional director. Name of the previous position holder: Tai, Chien-Cheng. Resume of the previous position holder: Senior Technical Specialist and Section Chief, Taiwan Intellectual Property Office. Name of the new position holder: Lin, Der-Sheng. Resume of the new position holder: Chief Secretary, the Industrial Development Administration, Taiwan's Ministry of Economic Affairs. Effective date of the new appointment is November 1, 2023.Reported Earnings • Aug 17Second quarter 2023 earnings released: NT$0.57 loss per share (vs NT$0.11 profit in 2Q 2022)Second quarter 2023 results: NT$0.57 loss per share (down from NT$0.11 profit in 2Q 2022). Revenue: NT$82.5m (down 84% from 2Q 2022). Net loss: NT$240.7m (down NT$286.0m from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 29% per year whereas the company’s share price has fallen by 24% per year.Reported Earnings • Apr 01Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: NT$0.68 (up from NT$0.10 in FY 2021). Revenue: NT$2.25b (up 37% from FY 2021). Net income: NT$291.0m (up NT$247.9m from FY 2021). Profit margin: 13% (up from 2.6% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 7.9%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$40.75, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 29x in the Biotechs industry in Asia. Total returns to shareholders of 50% over the past three years.Major Estimate Revision • Dec 06Consensus EPS estimates increase by 26%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from NT$2.10b to NT$2.18b. EPS estimate increased from NT$0.50 to NT$0.63 per share. Net income forecast to shrink 58% next year vs 38% growth forecast for Biotechs industry in Taiwan . Consensus price target of NT$52.00 unchanged from last update. Share price was steady at NT$36.60 over the past week.Reported Earnings • Nov 19Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$0.98 (up from NT$0.38 in 3Q 2021). Revenue: NT$1.09b (up 44% from 3Q 2021). Net income: NT$419.5m (up 161% from 3Q 2021). Profit margin: 39% (up from 21% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 109%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 84% growth forecast for the Biotechs industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Yung-Sheng Hsu was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 17Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: NT$0.11 (up from NT$0.38 loss in 2Q 2021). Revenue: NT$526.9m (up 499% from 2Q 2021). Net income: NT$45.3m (up NT$208.3m from 2Q 2021). Profit margin: 8.6% (up from net loss in 2Q 2021). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 69%. Over the next year, revenue is forecast to grow 17%, compared to a 882% growth forecast for the Biotechs industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 18First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: NT$0.55 loss per share (up from NT$0.58 loss in 1Q 2021). Revenue: NT$52.8m (up NT$45.9m from 1Q 2021). Net loss: NT$234.6m (loss narrowed 6.1% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is forecast to grow 48%, compared to a 9,387% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Price Target Changed • Apr 27Price target decreased to NT$53.00Down from NT$70.00, the current price target is provided by 1 analyst. New target price is 31% above last closing price of NT$40.50. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$0.34 for next year compared to NT$0.10 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Yung-Sheng Hsu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$0.10 (vs NT$3.04 in FY 2020)Full year 2021 results: EPS: NT$0.10 (down from NT$3.04 in FY 2020). Revenue: NT$1.64b (down 12% from FY 2020). Net income: NT$43.1m (down 97% from FY 2020). Profit margin: 2.6% (down from 66% in FY 2020). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 36%, compared to a 12,016% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 31Adimmune Corporation, Annual General Meeting, Jun 29, 2022Adimmune Corporation, Annual General Meeting, Jun 29, 2022. Location: No. 328, Junfu 18th Rd., Beitun Dist., Wagor International Banquet Hall Taichung City Taiwan Agenda: To consider 2021 Business Report; to consider Audit Committee's review of the 2021 Annual Final Accounting Books and Statements; to consider Report on 2021 employees' and directors' remuneration; to consider implementation of 2018 business improvement plan for cash capital increase; to consider 2021 Business Report and Financial Statements; to consider 2021 Earnings Distribution; to consider amendments to the Corporate Charter; and to consider other matters.お知らせ • Feb 12Adimmune Corporation Announces the Approval of the Company's Quadrivalent Influenza Vaccine from China's National Medical Products AdministrationAdimmune Corporation announced the marketing authorization of the Company's quadrivalent influenza vaccine is granted by China's National Medical Products Administration. Upon receiving the marketing authorization from China's National Medical Products Administration, the Company will initiate the marketing of quadrivalent influenza vaccine for adults.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.37 (vs NT$0.38 in 3Q 2020)The company reported a mediocre third quarter result with weaker profit margins, although earnings were flat and revenues improved. Third quarter 2021 results: Revenue: NT$753.3m (up 22% from 3Q 2020). Net income: NT$161.0m (flat on 3Q 2020). Profit margin: 21% (down from 26% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.38 loss per share (vs NT$0.35 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: NT$88.0m (up 40% from 2Q 2020). Net loss: NT$163.0m (loss widened 14% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 15First quarter 2021 earnings released: NT$0.58 loss per share (vs NT$0.045 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: NT$6.93m (down 98% from 1Q 2020). Net loss: NT$249.8m (loss widened NT$232.9m from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 26% share price gain to NT$62.90, the stock trades at a trailing P/E ratio of 20.7x. Average forward P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 246% over the past three years.分析記事 • Apr 05Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High QualityAdimmune Corporation ( TPE:4142 ) just reported healthy earnings but the stock price didn't move much. Investors are...Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$3.03 (vs NT$0.90 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.87b (up 44% from FY 2019). Net income: NT$1.24b (up NT$1.52b from FY 2019). Profit margin: 66% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 01Is Adimmune (TPE:4142) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Feb 22New 90-day high: NT$65.40The company is up 7.0% from its price of NT$61.40 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: NT$47.05The company is down 19% from its price of NT$58.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.分析記事 • Jan 07Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three YearsAdimmune Corporation ( TPE:4142 ) shareholders might be concerned after seeing the share price drop 28% in the last...Is New 90 Day High Low • Jan 04New 90-day low: NT$53.80The company is down 25% from its price of NT$71.80 on 06 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day low: NT$55.10The company is down 23% from its price of NT$71.70 on 16 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$617.7m (up 22% from 3Q 2019). Net income: NT$160.3m (up 45% from 3Q 2019). Profit margin: 26% (up from 22% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Nov 15Revenue misses expectationsRevenue missed analyst estimates by 5.1%.Is New 90 Day High Low • Oct 28New 90-day low: NT$61.80The company is down 10.0% from its price of NT$68.70 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Adimmune は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:4142 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,412-202-198-3N/A12/31/20251,402-240-261-5N/A9/30/20251,201-509-510-174N/A6/30/20251,614-227-399-120N/A3/31/20251,585-282-510-192N/A12/31/20241,557-243436668N/A9/30/20241,571-608-363-89N/A6/30/20241,657-608-262-75N/A3/31/20241,659-575-184100N/A12/31/20231,785-640-1,271-892N/A9/30/20231,810-165-392-109N/A6/30/20231,924-9-641-191N/A3/31/20232,369277-823-437N/A12/31/20222,252291-712-292N/A9/30/20222,613525-549-321N/A6/30/20222,279267-1,002-388N/A3/31/20221,84058-1,149-383N/A12/31/20211,79443-1,326-481N/A9/30/20211,670989-1721,139N/A6/30/20211,5349882471,230N/A3/31/20211,5091,0085021,274N/A12/31/20201,8691,2411,7682,322N/A9/30/20201,675-21-253108N/A6/30/20201,564-71-97149N/A3/31/20201,607-101-5275N/A12/31/20191,300-281N/A-253N/A9/30/20191,079-616N/A-206N/A6/30/2019887-733N/A-159N/A3/31/2019812-637N/A-170N/A12/31/2018822-618N/A-602N/A9/30/2018627-564N/A-451N/A6/30/2018538-670N/A-423N/A3/31/2018558-742N/A-377N/A12/31/2017563-760N/A7N/A9/30/2017648-670N/A-289N/A6/30/2017576-687N/A-390N/A3/31/2017637-643N/A-427N/A12/31/2016607-595N/A-774N/A9/30/2016437-717N/A-678N/A6/30/2016392-779N/A-538N/A3/31/2016308-767N/A-531N/A12/31/2015291-761N/A-374N/A9/30/2015312-655N/A-585N/A6/30/2015270-714N/A-391N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4142の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4142の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4142の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4142の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4142の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4142の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/13 21:49終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Adimmune Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Jianzheng WuCapital Securities CorporationHengyu FuMasterlink Securities Investment AdvisoryYijun ChenSinoPac Securities Investment Service1 その他のアナリストを表示
Major Estimate Revision • Dec 06Consensus EPS estimates increase by 26%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from NT$2.10b to NT$2.18b. EPS estimate increased from NT$0.50 to NT$0.63 per share. Net income forecast to shrink 58% next year vs 38% growth forecast for Biotechs industry in Taiwan . Consensus price target of NT$52.00 unchanged from last update. Share price was steady at NT$36.60 over the past week.
Price Target Changed • Apr 27Price target decreased to NT$53.00Down from NT$70.00, the current price target is provided by 1 analyst. New target price is 31% above last closing price of NT$40.50. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$0.34 for next year compared to NT$0.10 last year.
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.44 loss per share (vs NT$0.53 loss in 1Q 2025)First quarter 2026 results: NT$0.44 loss per share (improved from NT$0.53 loss in 1Q 2025). Revenue: NT$82.3m (up 14% from 1Q 2025). Net loss: NT$185.5m (loss narrowed 17% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 23% per year.
お知らせ • Mar 12Adimmune Corporation, Annual General Meeting, Jun 04, 2026Adimmune Corporation, Annual General Meeting, Jun 04, 2026. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan
Reported Earnings • Nov 16Third quarter 2025 earnings released: NT$0.04 loss per share (vs NT$0.63 profit in 3Q 2024)Third quarter 2025 results: NT$0.04 loss per share (down from NT$0.63 profit in 3Q 2024). Revenue: NT$475.3m (down 47% from 3Q 2024). Net loss: NT$18.3m (down 107% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.52 loss per share (vs NT$0.65 loss in 2Q 2024)Second quarter 2025 results: NT$0.52 loss per share (improved from NT$0.65 loss in 2Q 2024). Revenue: NT$108.6m (up 36% from 2Q 2024). Net loss: NT$218.8m (loss narrowed 20% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 16First quarter 2025 earnings released: NT$53.00 loss per share (vs NT$0.44 loss in 1Q 2024)First quarter 2025 results: NT$53.00 loss per share (further deteriorated from NT$0.44 loss in 1Q 2024). Revenue: NT$72.1m (up 64% from 1Q 2024). Net loss: NT$223.3m (loss widened 21% from 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
お知らせ • May 07Adimmune Corporation to Report Q1, 2025 Results on May 13, 2025Adimmune Corporation announced that they will report Q1, 2025 results on May 13, 2025
お知らせ • Mar 13Adimmune Corporation, Annual General Meeting, Jun 26, 2025Adimmune Corporation, Annual General Meeting, Jun 26, 2025. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan
New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change).
分析記事 • Jan 13There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price RiseAdimmune Corporation ( TWSE:4142 ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.62 (vs NT$0.63 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.62 (down from NT$0.63 in 3Q 2023). Revenue: NT$888.2m (down 8.7% from 3Q 2023). Net income: NT$263.3m (flat on 3Q 2023). Profit margin: 30% (up from 27% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.
Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Mei-Ling Hsiao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Aug 13Little Excitement Around Adimmune Corporation's (TWSE:4142) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 7.2x Adimmune Corporation ( TWSE:4142 ) is definitely a...
お知らせ • Aug 06Adimmune Corporation to Report Q2, 2024 Results on Aug 13, 2024Adimmune Corporation announced that they will report Q2, 2024 results on Aug 13, 2024
Reported Earnings • May 18First quarter 2024 earnings released: NT$0.44 loss per share (vs NT$0.59 loss in 1Q 2023)First quarter 2024 results: NT$0.44 loss per share (improved from NT$0.59 loss in 1Q 2023). Revenue: NT$43.9m (down 74% from 1Q 2023). Net loss: NT$184.0m (loss narrowed 26% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
お知らせ • May 05Adimmune Corporation to Report Q1, 2024 Results on May 10, 2024Adimmune Corporation announced that they will report Q1, 2024 results on May 10, 2024
Reported Earnings • Mar 31Full year 2023 earnings released: NT$1.52 loss per share (vs NT$0.68 profit in FY 2022)Full year 2023 results: NT$1.52 loss per share (down from NT$0.68 profit in FY 2022). Revenue: NT$1.79b (down 21% from FY 2022). Net loss: NT$639.9m (down 320% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 14Adimmune Corporation, Annual General Meeting, Jun 21, 2024Adimmune Corporation, Annual General Meeting, Jun 21, 2024. Location: No. 328, Junfu 18th Rd., Beitun Dist., Taichung City Taiwan Agenda: To consider 2023 Business Report; to consider audit Committee's review of the 2023 Annual Final Accounting Books and Statements; to consider election for one additional seat of independent director; and to transact other business.
お知らせ • Nov 02Adimmune Corporation Announces Change in Representative of its Institutional DirectorAdimmune Corporation announced the change in representative of the company’s institutional director. Name of the previous position holder: Tai, Chien-Cheng. Resume of the previous position holder: Senior Technical Specialist and Section Chief, Taiwan Intellectual Property Office. Name of the new position holder: Lin, Der-Sheng. Resume of the new position holder: Chief Secretary, the Industrial Development Administration, Taiwan's Ministry of Economic Affairs. Effective date of the new appointment is November 1, 2023.
Reported Earnings • Aug 17Second quarter 2023 earnings released: NT$0.57 loss per share (vs NT$0.11 profit in 2Q 2022)Second quarter 2023 results: NT$0.57 loss per share (down from NT$0.11 profit in 2Q 2022). Revenue: NT$82.5m (down 84% from 2Q 2022). Net loss: NT$240.7m (down NT$286.0m from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 29% per year whereas the company’s share price has fallen by 24% per year.
Reported Earnings • Apr 01Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: NT$0.68 (up from NT$0.10 in FY 2021). Revenue: NT$2.25b (up 37% from FY 2021). Net income: NT$291.0m (up NT$247.9m from FY 2021). Profit margin: 13% (up from 2.6% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 7.9%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Asia. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$40.75, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 29x in the Biotechs industry in Asia. Total returns to shareholders of 50% over the past three years.
Major Estimate Revision • Dec 06Consensus EPS estimates increase by 26%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from NT$2.10b to NT$2.18b. EPS estimate increased from NT$0.50 to NT$0.63 per share. Net income forecast to shrink 58% next year vs 38% growth forecast for Biotechs industry in Taiwan . Consensus price target of NT$52.00 unchanged from last update. Share price was steady at NT$36.60 over the past week.
Reported Earnings • Nov 19Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$0.98 (up from NT$0.38 in 3Q 2021). Revenue: NT$1.09b (up 44% from 3Q 2021). Net income: NT$419.5m (up 161% from 3Q 2021). Profit margin: 39% (up from 21% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 109%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 84% growth forecast for the Biotechs industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Yung-Sheng Hsu was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 17Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: NT$0.11 (up from NT$0.38 loss in 2Q 2021). Revenue: NT$526.9m (up 499% from 2Q 2021). Net income: NT$45.3m (up NT$208.3m from 2Q 2021). Profit margin: 8.6% (up from net loss in 2Q 2021). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 69%. Over the next year, revenue is forecast to grow 17%, compared to a 882% growth forecast for the Biotechs industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 18First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: NT$0.55 loss per share (up from NT$0.58 loss in 1Q 2021). Revenue: NT$52.8m (up NT$45.9m from 1Q 2021). Net loss: NT$234.6m (loss narrowed 6.1% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is forecast to grow 48%, compared to a 9,387% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Apr 27Price target decreased to NT$53.00Down from NT$70.00, the current price target is provided by 1 analyst. New target price is 31% above last closing price of NT$40.50. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$0.34 for next year compared to NT$0.10 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Yung-Sheng Hsu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$0.10 (vs NT$3.04 in FY 2020)Full year 2021 results: EPS: NT$0.10 (down from NT$3.04 in FY 2020). Revenue: NT$1.64b (down 12% from FY 2020). Net income: NT$43.1m (down 97% from FY 2020). Profit margin: 2.6% (down from 66% in FY 2020). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 36%, compared to a 12,016% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 31Adimmune Corporation, Annual General Meeting, Jun 29, 2022Adimmune Corporation, Annual General Meeting, Jun 29, 2022. Location: No. 328, Junfu 18th Rd., Beitun Dist., Wagor International Banquet Hall Taichung City Taiwan Agenda: To consider 2021 Business Report; to consider Audit Committee's review of the 2021 Annual Final Accounting Books and Statements; to consider Report on 2021 employees' and directors' remuneration; to consider implementation of 2018 business improvement plan for cash capital increase; to consider 2021 Business Report and Financial Statements; to consider 2021 Earnings Distribution; to consider amendments to the Corporate Charter; and to consider other matters.
お知らせ • Feb 12Adimmune Corporation Announces the Approval of the Company's Quadrivalent Influenza Vaccine from China's National Medical Products AdministrationAdimmune Corporation announced the marketing authorization of the Company's quadrivalent influenza vaccine is granted by China's National Medical Products Administration. Upon receiving the marketing authorization from China's National Medical Products Administration, the Company will initiate the marketing of quadrivalent influenza vaccine for adults.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.37 (vs NT$0.38 in 3Q 2020)The company reported a mediocre third quarter result with weaker profit margins, although earnings were flat and revenues improved. Third quarter 2021 results: Revenue: NT$753.3m (up 22% from 3Q 2020). Net income: NT$161.0m (flat on 3Q 2020). Profit margin: 21% (down from 26% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.38 loss per share (vs NT$0.35 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: NT$88.0m (up 40% from 2Q 2020). Net loss: NT$163.0m (loss widened 14% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 15First quarter 2021 earnings released: NT$0.58 loss per share (vs NT$0.045 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: NT$6.93m (down 98% from 1Q 2020). Net loss: NT$249.8m (loss widened NT$232.9m from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 26% share price gain to NT$62.90, the stock trades at a trailing P/E ratio of 20.7x. Average forward P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 246% over the past three years.
分析記事 • Apr 05Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High QualityAdimmune Corporation ( TPE:4142 ) just reported healthy earnings but the stock price didn't move much. Investors are...
Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$3.03 (vs NT$0.90 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.87b (up 44% from FY 2019). Net income: NT$1.24b (up NT$1.52b from FY 2019). Profit margin: 66% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 01Is Adimmune (TPE:4142) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Feb 22New 90-day high: NT$65.40The company is up 7.0% from its price of NT$61.40 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: NT$47.05The company is down 19% from its price of NT$58.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
分析記事 • Jan 07Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three YearsAdimmune Corporation ( TPE:4142 ) shareholders might be concerned after seeing the share price drop 28% in the last...
Is New 90 Day High Low • Jan 04New 90-day low: NT$53.80The company is down 25% from its price of NT$71.80 on 06 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day low: NT$55.10The company is down 23% from its price of NT$71.70 on 16 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$617.7m (up 22% from 3Q 2019). Net income: NT$160.3m (up 45% from 3Q 2019). Profit margin: 26% (up from 22% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 15Revenue misses expectationsRevenue missed analyst estimates by 5.1%.
Is New 90 Day High Low • Oct 28New 90-day low: NT$61.80The company is down 10.0% from its price of NT$68.70 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.